---
document_datetime: 2026-01-13 15:18:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/galenvita.html
document_name: galenvita.html
version: success
processing_time: 0.1080056
conversion_datetime: 2026-01-14 07:15:10.556099
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# GalenVita

[RSS](/en/individual-human-medicine.xml/270309)

##### Authorised

This medicine is authorised for use in the European Union

germanium (68Ge) chloride / gallium (68Ga) chloride Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on GalenVita](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

GalenVita is a radionuclide generator, a device used to obtain a solution containing gallium ( 68 Ga) chloride, a radioactive substance. GalenVita and the gallium ( 68 Ga) chloride solution it produces are not intended for direct use in patients.

The gallium ( 68 Ga) chloride solution is used for radiolabelling medicines, which are used during the body scan known as positron emission tomography (PET). Radiolabelling is a technique that tags molecules with a radioactive substance.

GalenVita contains germanium ( 68 Ge) chloride / gallium ( 68 Ga) chloride.

Expand section

Collapse section

## How is GalenVita used?

GalenVita and the gallium ( 68 Ga) chloride solution it produces should only be handled by specialists with appropriate training and expertise and can only be used in a designated authorised facility. Detailed instructions for use are included in the summary of product characteristics (information for healthcare professionals).

## How does GalenVita work?

GalenVita provides a gallium ( 68 Ga) chloride solution, which is used for radiolabelling medicines. These radiolabelled medicines can recognise and attach to certain cells in the body. The low amount of radioactivity present in the 68 Ga-labelled medicine can be detected during PET body scans, helping doctors with the diagnosis and monitoring of various diseases, including cancer.

## What benefits of GalenVita have been shown in studies?

Since 68 Ga-containing solutions obtained from 68 Ge/ 68 Ga-generators have been used for radiolabelling for several years, the company that markets GalenVita provided data from the medical literature showing its utility in clinical practice, mainly in the diagnosis of neuroendocrine tumours (cancers that form from cells that release hormones), meningiomas (a tumour that grows from the membranes that surround the brain and spinal cord, called the meninges) and prostate cancer.

## What are the risks associated with GalenVita?

Exposure to radiation may contribute to a risk of cancer or hereditary defects.

Side effects following the use of a medicine radiolabelled using the gallium ( 68 Ga) chloride solution obtained from GalenVita will depend on the specific medicine being used. For more information about possible side effects, read the package leaflet of the respective radiolabelled medicine.

## Why is GalenVita authorised in the EU?

68 Ga has a short half-life, meaning that it quickly loses the radioactivity necessary for radiolabelling. The use of a 68 Ge/ 68 Ga generator such as GalenVita is a suitable way to make gallium ( 68 Ga) chloride solution readily available for radiolabelling. GalenVita is expected to facilitate the process of radiolabelling in authorised facilities and to improve access to cancer diagnostics, which is considered a clinically relevant benefit. Potential risks to patients are considered low, as these can be minimised through quality control procedures and adequate instructions and training of the medical personnel handling GalenVita.

The European Medicines Agency therefore decided that GalenVita's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of GalenVita?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of GalenVita have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of GalenVita are continuously monitored. Suspected side effects reported with GalenVita are carefully evaluated and any necessary action taken to protect patients.

## Other information about GalenVita

GalenVita received a marketing authorisation valid throughout the EU on 8 January 2026.

GalenVita : EPAR - Medicine overview

Reference Number: EMA/35341/2023

English (EN) (132.05 KB - PDF)

**First published:** 13/01/2026

[View](/en/documents/overview/galenvita-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-948)

български (BG) (148.7 KB - PDF)

**First published:**

13/01/2026

[View](/bg/documents/overview/galenvita-epar-medicine-overview_bg.pdf)

español (ES) (120.98 KB - PDF)

**First published:**

13/01/2026

[View](/es/documents/overview/galenvita-epar-medicine-overview_es.pdf)

čeština (CS) (149.86 KB - PDF)

**First published:**

13/01/2026

[View](/cs/documents/overview/galenvita-epar-medicine-overview_cs.pdf)

dansk (DA) (120.51 KB - PDF)

**First published:**

13/01/2026

[View](/da/documents/overview/galenvita-epar-medicine-overview_da.pdf)

Deutsch (DE) (122.84 KB - PDF)

**First published:**

13/01/2026

[View](/de/documents/overview/galenvita-epar-medicine-overview_de.pdf)

eesti keel (ET) (118.47 KB - PDF)

**First published:**

13/01/2026

[View](/et/documents/overview/galenvita-epar-medicine-overview_et.pdf)

ελληνικά (EL) (143.61 KB - PDF)

**First published:**

13/01/2026

[View](/el/documents/overview/galenvita-epar-medicine-overview_el.pdf)

français (FR) (121.49 KB - PDF)

**First published:**

13/01/2026

[View](/fr/documents/overview/galenvita-epar-medicine-overview_fr.pdf)

hrvatski (HR) (141.13 KB - PDF)

**First published:**

13/01/2026

[View](/hr/documents/overview/galenvita-epar-medicine-overview_hr.pdf)

italiano (IT) (121.32 KB - PDF)

**First published:**

13/01/2026

[View](/it/documents/overview/galenvita-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147.34 KB - PDF)

**First published:**

13/01/2026

[View](/lv/documents/overview/galenvita-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (140.68 KB - PDF)

**First published:**

13/01/2026

[View](/lt/documents/overview/galenvita-epar-medicine-overview_lt.pdf)

magyar (HU) (139.74 KB - PDF)

**First published:**

13/01/2026

[View](/hu/documents/overview/galenvita-epar-medicine-overview_hu.pdf)

Malti (MT) (141.6 KB - PDF)

**First published:**

13/01/2026

[View](/mt/documents/overview/galenvita-epar-medicine-overview_mt.pdf)

Nederlands (NL) (120.67 KB - PDF)

**First published:**

13/01/2026

[View](/nl/documents/overview/galenvita-epar-medicine-overview_nl.pdf)

polski (PL) (142.74 KB - PDF)

**First published:**

13/01/2026

[View](/pl/documents/overview/galenvita-epar-medicine-overview_pl.pdf)

português (PT) (121.62 KB - PDF)

**First published:**

13/01/2026

[View](/pt/documents/overview/galenvita-epar-medicine-overview_pt.pdf)

română (RO) (137.95 KB - PDF)

**First published:**

13/01/2026

[View](/ro/documents/overview/galenvita-epar-medicine-overview_ro.pdf)

slovenčina (SK) (149.13 KB - PDF)

**First published:**

13/01/2026

[View](/sk/documents/overview/galenvita-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.89 KB - PDF)

**First published:**

13/01/2026

[View](/sl/documents/overview/galenvita-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.55 KB - PDF)

**First published:**

13/01/2026

[View](/fi/documents/overview/galenvita-epar-medicine-overview_fi.pdf)

svenska (SV) (119 KB - PDF)

**First published:**

13/01/2026

[View](/sv/documents/overview/galenvita-epar-medicine-overview_sv.pdf)

GalenVita : EPAR - Risk management plan

English (EN) (580.96 KB - PDF)

**First published:** 13/01/2026

[View](/en/documents/rmp/galenvita-epar-risk-management-plan_en.pdf)

## Product information

GalenVita : EPAR - Product information

English (EN) (2.77 MB - PDF)

**First published:** 13/01/2026

[View](/en/documents/product-information/galenvita-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-689)

български (BG) (2.8 MB - PDF)

**First published:**

13/01/2026

[View](/bg/documents/product-information/galenvita-epar-product-information_bg.pdf)

español (ES) (2.88 MB - PDF)

**First published:**

13/01/2026

[View](/es/documents/product-information/galenvita-epar-product-information_es.pdf)

čeština (CS) (2.87 MB - PDF)

**First published:**

13/01/2026

[View](/cs/documents/product-information/galenvita-epar-product-information_cs.pdf)

dansk (DA) (2.69 MB - PDF)

**First published:**

13/01/2026

[View](/da/documents/product-information/galenvita-epar-product-information_da.pdf)

Deutsch (DE) (2.75 MB - PDF)

**First published:**

13/01/2026

[View](/de/documents/product-information/galenvita-epar-product-information_de.pdf)

eesti keel (ET) (2.71 MB - PDF)

**First published:**

13/01/2026

[View](/et/documents/product-information/galenvita-epar-product-information_et.pdf)

ελληνικά (EL) (2.9 MB - PDF)

**First published:**

13/01/2026

[View](/el/documents/product-information/galenvita-epar-product-information_el.pdf)

français (FR) (2.25 MB - PDF)

**First published:**

13/01/2026

[View](/fr/documents/product-information/galenvita-epar-product-information_fr.pdf)

hrvatski (HR) (2.78 MB - PDF)

**First published:**

13/01/2026

[View](/hr/documents/product-information/galenvita-epar-product-information_hr.pdf)

íslenska (IS) (2.59 MB - PDF)

**First published:**

13/01/2026

[View](/is/documents/product-information/galenvita-epar-product-information_is.pdf)

italiano (IT) (2.56 MB - PDF)

**First published:**

13/01/2026

[View](/it/documents/product-information/galenvita-epar-product-information_it.pdf)

latviešu valoda (LV) (2.78 MB - PDF)

**First published:**

13/01/2026

[View](/lv/documents/product-information/galenvita-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.78 MB - PDF)

**First published:**

13/01/2026

[View](/lt/documents/product-information/galenvita-epar-product-information_lt.pdf)

magyar (HU) (2.9 MB - PDF)

**First published:**

13/01/2026

[View](/hu/documents/product-information/galenvita-epar-product-information_hu.pdf)

Malti (MT) (3.15 MB - PDF)

**First published:**

13/01/2026

[View](/mt/documents/product-information/galenvita-epar-product-information_mt.pdf)

Nederlands (NL) (2.83 MB - PDF)

**First published:**

13/01/2026

[View](/nl/documents/product-information/galenvita-epar-product-information_nl.pdf)

norsk (NO) (2.91 MB - PDF)

**First published:**

13/01/2026

[View](/no/documents/product-information/galenvita-epar-product-information_no.pdf)

polski (PL) (2.54 MB - PDF)

**First published:**

13/01/2026

[View](/pl/documents/product-information/galenvita-epar-product-information_pl.pdf)

português (PT) (2.73 MB - PDF)

**First published:**

13/01/2026

[View](/pt/documents/product-information/galenvita-epar-product-information_pt.pdf)

română (RO) (2.71 MB - PDF)

**First published:**

13/01/2026

[View](/ro/documents/product-information/galenvita-epar-product-information_ro.pdf)

slovenčina (SK) (2.83 MB - PDF)

**First published:**

13/01/2026

[View](/sk/documents/product-information/galenvita-epar-product-information_sk.pdf)

slovenščina (SL) (2.91 MB - PDF)

**First published:**

13/01/2026

[View](/sl/documents/product-information/galenvita-epar-product-information_sl.pdf)

Suomi (FI) (2.77 MB - PDF)

**First published:**

13/01/2026

[View](/fi/documents/product-information/galenvita-epar-product-information_fi.pdf)

svenska (SV) (2.6 MB - PDF)

**First published:**

13/01/2026

[View](/sv/documents/product-information/galenvita-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

GalenVita : EPAR - All authorised presentations

English (EN) (74.86 KB - PDF)

**First published:** 13/01/2026

[View](/en/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-35)

български (BG) (92.51 KB - PDF)

**First published:**

13/01/2026

[View](/bg/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_bg.pdf)

español (ES) (85.44 KB - PDF)

**First published:**

13/01/2026

[View](/es/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_es.pdf)

čeština (CS) (85.68 KB - PDF)

**First published:**

13/01/2026

[View](/cs/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (78.17 KB - PDF)

**First published:**

13/01/2026

[View](/da/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (80.24 KB - PDF)

**First published:**

13/01/2026

[View](/de/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (83.69 KB - PDF)

**First published:**

13/01/2026

[View](/et/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (92.54 KB - PDF)

**First published:**

13/01/2026

[View](/el/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_el.pdf)

français (FR) (68.04 KB - PDF)

**First published:**

13/01/2026

[View](/fr/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.75 KB - PDF)

**First published:**

13/01/2026

[View](/hr/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (74.39 KB - PDF)

**First published:**

13/01/2026

[View](/is/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_is.pdf)

italiano (IT) (83.86 KB - PDF)

**First published:**

13/01/2026

[View](/it/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (83.18 KB - PDF)

**First published:**

13/01/2026

[View](/lv/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (84.51 KB - PDF)

**First published:**

13/01/2026

[View](/lt/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (86.57 KB - PDF)

**First published:**

13/01/2026

[View](/hu/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (90.72 KB - PDF)

**First published:**

13/01/2026

[View](/mt/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (80.25 KB - PDF)

**First published:**

13/01/2026

[View](/nl/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (76.24 KB - PDF)

**First published:**

13/01/2026

[View](/no/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_no.pdf)

polski (PL) (87.68 KB - PDF)

**First published:**

13/01/2026

[View](/pl/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_pl.pdf)

português (PT) (82.32 KB - PDF)

**First published:**

13/01/2026

[View](/pt/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_pt.pdf)

română (RO) (84.55 KB - PDF)

**First published:**

13/01/2026

[View](/ro/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (88.6 KB - PDF)

**First published:**

13/01/2026

[View](/sk/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (81.64 KB - PDF)

**First published:**

13/01/2026

[View](/sl/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (82.43 KB - PDF)

**First published:**

13/01/2026

[View](/fi/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (79.23 KB - PDF)

**First published:**

13/01/2026

[View](/sv/documents/all-authorised-presentations/galenvita-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine GalenVita Active substance

- germanium (68Ge) chloride
- gallium (68Ga) chloride

International non-proprietary name (INN) or common name

- germanium (68Ge) chloride
- gallium (68Ga) chloride

Therapeutic area (MeSH) Radionuclide Imaging Anatomical therapeutic chemical (ATC) code V09X

### Pharmacotherapeutic group

Diagnostic radiopharmaceuticals

### Therapeutic indication

This radionuclide generator is not intended for direct use in patients.

The sterile eluate (gallium (68Ga) chloride solution) from the radionuclide generator GalenVita is indicated for *in vitro* radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling with such eluate, to be used for positron emission tomography (PET) imaging.

## Authorisation details

EMA product number EMEA/H/C/006639 Marketing authorisation holder

Curium Romania S.R.L.

Strada Gradinarilor Nr1 077145 Pantelimon Romania

Opinion adopted 13/11/2025 Marketing authorisation issued 08/01/2026

## Assessment history

## Initial marketing authorisation documents

GalenVita : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/200195/2025

English (EN) (695.88 KB - PDF)

**First published:** 13/01/2026

[View](/en/documents/assessment-report/galenvita-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for GalenVita

Adopted

Reference Number: EMA/354268/2025

English (EN) (162.66 KB - PDF)

**First published:** 14/11/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-galenvita_en.pdf)

#### News on GalenVita

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025) 14/11/2025

**This page was last updated on** 13/01/2026

## Share this page

[Back to top](#main-content)